KalVista Pharmaceuticals won FDA accelerated approval for Ekterly (sebetralstat), the first oral on-demand treatment for hereditary angioedema (HAE) in patients aged 12 and older. The approval followed a delay attributed to FDA resource constraints rather than product concerns. Clinical trials showed rapid symptom relief compared to placebo, with competitive dosing advantages over existing injectable therapies. Financially, the drug is poised for meaningful market impact, supported by licensing deals in Canada and Japan.